Table 1.
Selected clinical trials of CAR-T cell therapy in ALL.
| Institute | CAR (target & generation) | Sample |
Effective No. of participants | Outcomea | Publishing Year and Ref. | |
|---|---|---|---|---|---|---|
| Number (M/F) | Age* | |||||
| Memorial Sloan-Kettering Cancer Center | CD19 2nd CD28 | 16 (12/4) | Adult | 15b | CR rate: 88% | 201439 |
| Fred Hutchinson Cancer Research Center | CD19 2nd 4-1BB | 29c | Not available | 26 | CR rate: 93% | 201548 |
| National Cancer Institute | CD19 2nd CD28 | 21d (14/7) | 14.71 ± 6.64 | 21 | CR rate :66.7% | 201417, 32 |
| University of Pennsylvania | CD19 2nd 4-1BB | 30 (18/12) | Children & Adult | 30 | CR rate: 90% | 201420, 41 |
| University of Pennsylvania | CD19 2nd 4-1BB | 27c | Adult | 27 | 3 CR in cohort 1 and 2; 3 CR in cohort 3; 75%CR and 8.3%PR in cohort 4 | 201643 |
| Hebei Yanda Lu Daopei Hospital | CD19 2nd 4-1BB | 42 (28/14)e | Children & adult | 40f | CR rate: 90% | 201742 |
| 9 (4/5)e | Children & adult | 9 | All patients achieved MRD- | 201742 | ||
| Peking University People's Hospital | CD19 4th (CD28/4-1BB/CD27/inducible apoptotic caspase9 | 6 (1/5) | 26.50 ± 13.62 | 5g | 5 achieved minimal residual disease (MRD)-negative remissionh | 201766 |
Abbreviations: aGVHD, acute Graft-versus-host disease; ALL, acute lymphoblastic leukemia; BM, bone marrow; CAR T cell, chimeric antigen receptor T cell; CR, complete remission; M/F, male and female; MRD, minimal residual disease; PR, partial remission; Ref, reference; SEM, standard error of mean.
The denominator in the calculation is the total sample number.
One patient had only gross extramedullary disease (no detectable disease in the BM).
No gender indicated.
Twenty ALL patients.
This clinical trial has two groups: one includes 42 primary refractory/hematological relapsed and 9 refractory minimal residual disease (MRD) by flow cytometry B-ALL patients.
Two patients died from treatment-related mortality early in the trial (on days 21 and 24).
One patient was discharged automatically without evaluation after developing severe thrombotic microangiopathies.
Four of five responsive patients relapsed after 2–7 months, and one died of sepsis following MRD-negative remission after a second infusion. None of the other second infusion recipients achieved a second complete remission. Two and one patient developed grade 2 and 3 aGVHD, respectively.
Ages of patients are expressed as mean ± SEM if the data are available.